Literature DB >> 23824905

How many cervical cancer cases can potentially be prevented using a more sensitive screening test at young age?

Inge M C M de Kok1, Joost van Rosmalen, Kirsten Rozemeijer, Corine Penning, Marjolein van Ballegooijen.   

Abstract

The human papilloma virus (HPV) DNA test has higher sensitivity than cytology for cervical cancer screening. Therefore, cervical cancer cases that are missed by cytology could potentially be identified if we use primary HPV testing. Studies showed that HPV screening is the preferred primary test at age 35 and over. Given the high prevalence of harmless HPV infections, the use of HPV testing at younger age is less obvious. The number of cancers in young age is often mentioned to indicate the possible benefits of a more sensitive test. We actually estimated the proportion of those cases that is potentially preventable in The Netherlands by the use of a more sensitive screen-test at the first screening age 30, given that the more sensitive test is used at age 35 and over. We analysed the screening history of women diagnosed with cervical cancer in the period 2004 to March 2009, using data from the Dutch National Pathology Registry. Only 15-30% (two to four cases per 100,000 women) of the cases was preceded by negative cytology under age 35 and therefore could have been prevented by a more sensitive test at age 30. The lower the screening coverage and the shorter the screening interval in those screened at young age, the smaller the gain of a more sensitive test. So, as long as the current screening pattern is not changed, the majority of the cervical cancer cases at young age would still occur even when applying a more sensitive test at the younger ages.
© 2013 UICC.

Entities:  

Keywords:  cervical cancer; cytology; human papilloma virus DNA test; screening; young women

Mesh:

Year:  2013        PMID: 23824905     DOI: 10.1002/ijc.28366

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions.

Authors:  Raquel Ibáñez; María Alejo; Neus Combalia; Xavier Tarroch; Josefina Autonell; Laia Codina; Montserrat Culubret; Francesc Xavier Bosch; Silvia de Sanjosé
Journal:  Biomed Res Int       Date:  2015-06-09       Impact factor: 3.411

2.  Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.

Authors:  Emily A Burger; Kine Pedersen; Stephen Sy; Ivar Sønbø Kristiansen; Jane J Kim
Journal:  Br J Cancer       Date:  2017-08-03       Impact factor: 7.640

3.  The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.

Authors:  Steffie K Naber; Inge M C M de Kok; Suzette M Matthijsse; Marjolein van Ballegooijen
Journal:  Cancer Causes Control       Date:  2016-03-12       Impact factor: 2.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.